Abstract: A modified lectin protein is provided having at least one amino acid modification in an amino acid sequence of SEQ ID NO. 1 orin an amino acid sequence having at least 60% homology thereto. The amino acid modification is selected from one of more of the following: at least one amino acid modification in a carbohydrate binding site; at least one amino acid modification in the N-terminus; at least one amino acid modification at position 76; or at least one amino acid modification at position 44 or 89. The modified lectin protein does not consist of the amino acid sequence of any of SEQ ID NOs: 2 to 4.

Abstract: A recombinant lectin for use in a method of treatment of cancer by inhibiting angiogenesis in a subject. The treatment comprises administration of a therapeutically effective amount of the recombinant lectin.

Abstract: The present disclosure relates to a stable, reproducible and bioequivalent apixaban compositions, wherein the composition comprising apixaban having a D90 particle size of more than 100 microns, preferably between 300 and 1000 microns, and more preferably between 350 and 800 microns, and further comprising one or more pharmaceutically acceptable excipients. The present disclosure further provides a process for preparation of a pharmaceutical composition comprising apixaban by wet granulation.

Abstract: The present invention relates to stable formulations of recombinant proteins. The invention specifically relates to the formulations of recombinant lectins derived from Sclerotium rolfsii lectin. The formulation comprises recombinant lectin derived from Sclerotium rolfsii lectin and a pharmaceutically acceptable excipient. The invention also relates to the stable liquid and/or lyophilized formulations comprising recombinant lectins derived from Sclerotium rolfsii lectin.

Abstract: The present invention relates to the combination chemotherapy with recombinant lectin protein. The invention specifically relates to the cytotoxic effect of recombinant lectin protein having amino acid sequence of SEQ ID NO: 1 in combination with other therapeutic agents, wherein the other therapeutic agents are anti-cancer agents. The combinations are highly synergistic and efficacious against several cancers.

Abstract: The present disclosure provides an extended release composition of tofacitinib for oral administration, and methods of making the composition. The extended release composition employs a matrix drug core comprising tofacitinib or a pharmaceutically acceptable salt thereof and at least one release controlling polymer. The matrix drug core is surrounded by a soluble functional coating comprising at least one coating polymer and at least one pharmaceutically acceptable excipient.

Abstract: A pharmaceutical composition containing cinacalcet or pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable excipients. A pharmaceutical composition containing cinacalcet or pharmaceutically acceptable salts thereof having a particle size distribution D90 equal to or less than 20 ?m, D50 equal to or less than 10 ?m, and D10 equal to or less than 5 ?m and one or more and binders in an amount of 0.9% w/w or less, relative to the total weight of composition, where the composition is not free of binder and that the total amount of binder does not exceed 0.9% w/w relative to the total weight of the composition.

Abstract: The present invention relates to a disintegrant free pharmaceutical composition comprising apremilast or pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable excipients. Particularly the present invention relates to disintegrant free immediate release dosage form comprising apremilast or pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable excipients. It further relates to process of preparing such composition and its use in psoriatic arthritis and psoriasis.

Abstract: The present invention relates to a lectin for use in the treatment, reduction in progression and curing of inflammation in a subject in need thereof. Pharmaceutical compositions comprising said lectin are also described. The lectin may comprise an amino acid sequence having sequence of SEQ ID NO: 1 or at least 60% homology to SEQ ID NO: 1.

Abstract: The present invention relates to the process to prepare recombinant lectin having amino acid sequence of SEQ ID NO:1, wherein the process comprises fed-batch fermentation of a clone in a host cell at specific feeding rate with carbon to Nitrogen ratio of 3:1 to 6:1. The invention also relates to the process of purification of recombinant lectin having amino acid sequence of SEQ ID NO: 1.

Abstract: A modified lectin protein is provided having at least one amino acid modification in an amino acid sequence of SEQ ID NO. 1 or in an amino acid sequence having at least 60% homology thereto. The amino acid modification is selected from one of more of the following: at least one amino acid modification in a carbohydrate binding site; at least one amino acid modification in the N-terminus; at least one amino acid modification at position 76; or at least one amino acid modification at position 44 or 89. The modified lectin protein does not consist of the amino acid sequence of any of SEQ ID NOs: 2 to 4.

Abstract: The present invention relates to the leader sequence for higher expression of recombinant proteins. The invention further relates to the process for preparation of insulin and insulin analogues using leader sequence. The leader peptides significantly increase the expression of pre-proinsulin. The present invention also relates to the protein sequences prepared by fusion of fragments with the leader sequences of the present invention. The invention is demonstrated by preparing and Insulin and its analogues using said leader sequences.

Abstract: The invention relates to vortioxetine hydrobromide having particle size distribution of D98 100-200?, D50 35-90? and D5 7-30? as well as to a stable, reproducible and bioequivalent pharmaceutical composition comprising vortioxetine hydrobromide having particle size distribution of D98 100-200?, D50 35-90? and D5 7-30? and one or more pharmaceutically acceptable excipient. It is produced by wet granulation techniques.

Abstract: A system and method to generate and deploy a customized cloud device application has been described. A platform broker analyzes a deployment information of a software service included in the customized cloud device application. Based on the analysis, the platform broker determines whether the software service is to be deployed at a cloud resource or devices. Based on the determination and a composition pattern, the platform broker sends a software service deployment request to a cloud broker and a device broker. Based on the software service deployment request, an instance of the software service is generated and the generated instance of the software service is deployed to one of the cloud resource or one or more devices. Finally, the generated instance of the customized cloud device application bound to the deployed instance of the software service is deployed to one of the one or more cloud resources and the device.

Abstract: A system and method to auto-determine and install missing components to a to a to-be-managed device by a single execution of unique device setup command has been described. Initially based on a received request, a unique device setup command is generated to on board a device on cloud device management system. Next the unique device setup command is executed that executes several operations including: auto-determining whether the device has required Operating System (OS), system architecture, and one or more software components including a control panel slave to allow retrieval of device monitoring data from the device. The execution of unique device address also execute the operation of installing a control plane slave on the device in communication with a control plane master at the cloud device management system to manage the plurality of devices, when the device has the required OS, architecture, and the one or more software components.

Abstract: A system and method to manage communication between a plurality of heterogeneous devices and a cloud has been described. A speaker communication property of a speaker node executing at one of the plurality of heterogeneous devices and the cloud in a first network is compared with a listener communication property of a listener node executing at another of the plurality of devices in a second network. A message-type agnostic listener proxy included in the first network is then generated based on the comparison. Next a message-type agnostic buffer including serialized message corresponding to a message sent by the speaker node is received at the first communication bridge in the first network. Finally, the message-type agnostic speaker proxy forwards the serialized message included in the message-type agnostic buffer to the listener node in the second network.

Abstract: A system and method to generate and deploy a cloud device application has been described. Initially a software service is selected from a software service store to generate the cloud device application. A selection of composition pattern is then received for generating a cloud device application including the software service. Based on the composition pattern an instance of the software service is generated and deployed at cloud and one or more devices. Next an instance of the application is generated and bound to the deployed instance of the software service. Finally the instance of the application bound to the deployed instance of the software service is deployed to the cloud and the one or more devices.

Abstract: A system and method to build and deploy a cloud device application a cloud and a plurality of devices has been described. Initially a selection of software executable code and runtime architecture of one of the cloud and the plurality of devices is received for deploying the cloud device application including the software executable code. Next a builder image is selected for generating a software executable image corresponding to the software executable code. Next a build process is executed to generate the software executable image corresponding to the software executable code based on the selected builder process. Finally the generated software executable image on one of the cloud and one of the plurality of devices is deployed based on the runtime architecture.

Abstract: A system and method to manage a plurality of devices has been described. Initially a device manager server in a cloud device management system, sends a selection of one or more device monitoring parameters to retrieve device monitoring data from a device from the plurality of devices. Next a device monitoring data is received corresponding to the selected one or more device monitoring parameters retrieved from the device and stored in a log database, and a metric database at the cloud device management system. Next one or more device monitoring data-based operations are executed at the cloud device management system based on the device monitoring data stored at the log database and the metric database. Finally, the result of execution is displayed at a console of the cloud device management system.

Abstract: The present invention relates to enzymatic reduction of 3-quinuclidinone to (R)-3-quinuclidinol (Scheme I), by reacting 3-quinuclidinone with a variant of ketoreductase enzyme derived from Rhodotorula rubra. The invention also relates to enzymatically produced (R)-3-quinuclidinol wherein the substrate loading capacity of the enzyme is not less than 100 g/L.